Skip to main content
Log in

Screening for Prostate Cancer

Implications for Drug Therapy

  • Leading Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Gerber G, Chodak GW. Routine screening for cancer of the prostate. J Natl Cancer Inst 1991; 83: 329–35

    Article  PubMed  CAS  Google Scholar 

  2. Garnick MB. Prostate cancer: screening diagnosis and management. Ann Intern Med 1993; 118: 804–18

    PubMed  CAS  Google Scholar 

  3. Catalona WJ. Screening for prostate cancer. Lancet 1994; 343: 1437

    PubMed  CAS  Google Scholar 

  4. Adolfsson J, Steineck G, Whitmore WF. Recent results of management of palpable clinical localised prostate cancer. Cancer 1993; 72: 310–22

    Article  PubMed  CAS  Google Scholar 

  5. Stamey TA, McNeal JE. Adenocarcinoma of the prostate. In: Walsh PC, Retick AB, et al., editors. Campbell’s urology. 6th ed. Philadelphia: WB Saunders 1991; 1159–215

    Google Scholar 

  6. Smith PH. The case for no initial treatment of localised prostate cancer. Urol Clin North Am 1990; 17: 827–34

    PubMed  CAS  Google Scholar 

  7. Sogani PC, Fair WR. Treatment of advanced prostate cancer. Urol Clin North Am 1987; 14: 353–71

    PubMed  CAS  Google Scholar 

  8. Wilson JMG, Jungner G. Principals and practice of screening for disease. Geneva: World Health Organisation, 1968

    Google Scholar 

  9. Harwood RH. Should we screen for prostate cancer. Age Ageing 1994; 23: 164–8

    Article  PubMed  CAS  Google Scholar 

  10. Adami HO, Baron JA, Rothman KJ. Ethics of a prostate cancer screening trial. Lancet 1994; 343: 958–60

    Article  PubMed  CAS  Google Scholar 

  11. Mettlin C. The status of prostate cancer early detection. Cancer 1993; 72: 1050–5

    Article  PubMed  CAS  Google Scholar 

  12. Lu-Yao GL, Greenberg RE. Changes in prostate cancer incidence and treatment in USA. Lancet 1994; 343: 251–4

    Article  PubMed  CAS  Google Scholar 

  13. Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localised prostate cancer. N Engl J Med 1994; 330: 242–8

    Article  PubMed  CAS  Google Scholar 

  14. Whitmore WF. Overview: historical and contemporary. Natl Cancer Inst Monogr 1988; 7: 7–11

    Google Scholar 

  15. Meyers FJ. Tumor biology in explanation of the failure of screening and in determining of future strategies. JAMA 1986; 80: 911–6

    CAS  Google Scholar 

  16. Gittes RF. Carcinoma of the prostate. N Engl J Med 1991; 324: 236–45

    Article  PubMed  CAS  Google Scholar 

  17. Kramer BS, Brown ML, Prorok PC, et al. Prostate cancer: what we know and what we need to know. Ann Intern Med 1993; 914–23

  18. Thompson IM, Rounder JB, Teague JL. Impact of routine screening for carcinoma of the prostate on stage distribution. J Urol 1987; 137: 424–6

    PubMed  CAS  Google Scholar 

  19. Santen RJ. Endocrine treatment of prostate cancer. J Clin Endocrinol Metab 1992: 75: 685–9

    Article  PubMed  CAS  Google Scholar 

  20. Ruizeveld de Winter JA, Jannsen PJA, Sleddens HMEB, et al. Androgen receptor status in localised and locally progressive hormone refractory human prostate cancer. Am J Pathol 1994; 144: 735–46

    PubMed  CAS  Google Scholar 

  21. Veterans Administration Co-operative Urological Research Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967; 124; 1011–7

    Google Scholar 

  22. Veterans Administration Co-operative Urological Research Group. Carcinoma of the prostate: treatment comparisons. J Urol 1967; 98: 516–22

    Google Scholar 

  23. Byar DP, VACURG. Survival of patients with incidentally found microscopic cancer of the prostate: results of a clinical trial of conservative treatment. J Urol 1972; 108: 908–13

    PubMed  CAS  Google Scholar 

  24. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the VACURG studies. NCI Monographs 1988; 7: 165–70

    PubMed  Google Scholar 

  25. Byar DP. The VACURG studies of cancer of the prostate. Cancer 1973; 1126–30

  26. Kozlowski JM, Ellis WJ, Grayhack JT. Advanced prostate carcinoma: early versus late endocrine therapy. Urol Clin North Am 18: 15–24

  27. Fellows GJ, Clark PB, Beynon LL, et al. Treatment of advanced localised prostatic cancer by orchiectomy, radiotherapy or combined treatment: an MRC study. Br J Urol 1992; 70; 304–9

    PubMed  CAS  Google Scholar 

  28. Fossa SD, Aaronson NK, Newling D, et al. Quality of life and treatment of hormone resistant prostatic cancer. Eur J Cancer 1990; 26; 1133–6

    Article  PubMed  CAS  Google Scholar 

  29. Kirk D. Trials and tribulations in prostate cancer. Br J Urol 1987; 59: 375–9

    Article  PubMed  CAS  Google Scholar 

  30. Research ethics. MRC multicentre trial of orchiectomy in carcinoma of the prostate. Bull Inst Med Ethics 1986; March: 1–7

  31. De Kernion JB, Neuwirth H, Stein A, et al. Prognosis of patients with stage D1 prostate cancer following radical prostatectomy with and without early endocrine therapy. J Urol 1990; 144: 700–3

    Google Scholar 

  32. Kramolowsky EV. The value of testosterone deprivation in stage D1 carcinoma of the prostate. J Urol 1988; 139: 1242–4

    PubMed  CAS  Google Scholar 

  33. Zincke H. Extended experience with surgical treatment of stage D1 adenocarcinoma of the prostate: significant influences of immediate adjuvant hormonal treatment (orchiectomy) on outcome. Urology 1989; 33 Suppl. 5: 27–36

    Article  PubMed  CAS  Google Scholar 

  34. Belt E, Schroder FH. Total perineal prostatectomy for carcinoma of the prostate. J Urol 1972; 107: 91–6

    PubMed  CAS  Google Scholar 

  35. Grossman HB. Hormonal therapy of prostatic carcinoma: is there a rationale for delayed treatment? Urology 1986; 27: 199–204

    Article  PubMed  CAS  Google Scholar 

  36. Harris MG, Coleman SG, Faulds D, Chrisp P. Nilutamide: a review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy in Prostate Cancer. Drugs Aging 1993; 3(1): 9–25

    Article  PubMed  CAS  Google Scholar 

  37. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic cancer. N Engl J Med 1989; 321: 419–24

    Article  PubMed  CAS  Google Scholar 

  38. Dearnaly DP. Cancer of the prostate. BMJ 1994; 308: 780–4

    Article  Google Scholar 

  39. Waxman J, Saini A. The current status of scientific research and hormonal treatments for carcinoma of the prostate. Br J Cancer 1991; 64: 419–21

    Article  PubMed  CAS  Google Scholar 

  40. Bilgrami S, Greenberg B. Cost-effectiveness of prostate cancer screening and treatment. Ann Intern Med 1993; 119: 1054–5

    PubMed  CAS  Google Scholar 

  41. Schroder FH. Adjuvant endocrine treatment in early prostatic cancer. Acta Oncologica 1991; 30: 255–8

    Article  PubMed  CAS  Google Scholar 

  42. Paulson DF, Lin GH, Hinshaw W, et al. Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol 1982; 128: 502–5

    PubMed  CAS  Google Scholar 

  43. Fleming C, Wasson JH, Albertsen PC, et al. A decision analysis of alternate treatment strategies for clinically localised prostate cancer. JAMA 1993; 269: 2650–8

    Article  PubMed  CAS  Google Scholar 

  44. Sox HC, Blatt M, Marton K. Medical decision making. London: Butterworths, 1988

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harwood, R.H. Screening for Prostate Cancer. Drugs & Aging 6, 345–350 (1995). https://doi.org/10.2165/00002512-199506050-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199506050-00001

Keywords

Navigation